NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has scheduled its first quarter 2025 financial results announcement for May 15, 2025, after market close. The company will release results through a press release available on their investor relations website, followed by a conference call at 4:30 PM ET.
Interested parties can access the conference call via webcast on the company's website or by telephone using the following dial-in numbers: +1-800-717-1738 (domestic) or +1-646-307-1865 (international).
NRx Pharmaceuticals (NASDAQ: NRXP), un'azienda biofarmaceutica in fase clinica, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 15 maggio 2025, dopo la chiusura dei mercati. I risultati saranno diffusi tramite un comunicato stampa disponibile sul sito web delle relazioni con gli investitori, seguito da una conference call alle 16:30 ET.
Gli interessati potranno partecipare alla conference call tramite webcast sul sito web della società o telefonicamente utilizzando i seguenti numeri: +1-800-717-1738 (nazionale) o +1-646-307-1865 (internazionale).
NRx Pharmaceuticals (NASDAQ: NRXP), una empresa biofarmacéutica en etapa clínica, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 15 de mayo de 2025, después del cierre del mercado. La compañía publicará los resultados mediante un comunicado de prensa disponible en su sitio web de relaciones con inversionistas, seguido de una llamada conferencia a las 4:30 PM ET.
Los interesados pueden acceder a la llamada conferencia a través de una transmisión en vivo en el sitio web de la empresa o por teléfono utilizando los siguientes números: +1-800-717-1738 (nacional) o +1-646-307-1865 (internacional).
NRx Pharmaceuticals (NASDAQ: NRXP)는 임상 단계 바이오제약 회사로, 2025년 1분기 재무 결과 발표를 2025년 5월 15일 시장 마감 후에 예정하고 있습니다. 회사는 투자자 관계 웹사이트를 통해 보도 자료를 공개한 후, 동부시간 오후 4시 30분에 컨퍼런스 콜을 진행할 예정입니다.
관심 있는 분들은 회사 웹사이트의 웹캐스트를 통해 또는 다음 전화번호를 이용해 컨퍼런스 콜에 참여할 수 있습니다: +1-800-717-1738 (국내), +1-646-307-1865 (국제).
NRx Pharmaceuticals (NASDAQ : NRXP), une entreprise biopharmaceutique en phase clinique, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 15 mai 2025, après la clôture du marché. La société publiera les résultats via un communiqué de presse disponible sur son site web dédié aux relations investisseurs, suivi d'une conférence téléphonique à 16h30 ET.
Les personnes intéressées peuvent accéder à la conférence téléphonique via un webcast sur le site de la société ou par téléphone en utilisant les numéros suivants : +1-800-717-1738 (domestique) ou +1-646-307-1865 (international).
NRx Pharmaceuticals (NASDAQ: NRXP), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 15. Mai 2025 nach Börsenschluss geplant. Das Unternehmen wird die Ergebnisse über eine Pressemitteilung auf seiner Investor-Relations-Website veröffentlichen, gefolgt von einer Telefonkonferenz um 16:30 Uhr ET.
Interessierte können an der Telefonkonferenz über einen Webcast auf der Unternehmenswebsite oder telefonisch unter folgenden Rufnummern teilnehmen: +1-800-717-1738 (national) oder +1-646-307-1865 (international).
- None.
- None.
A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information: | |
Matthew Duffy | Brian Korb |
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-to-report-first-quarter-2025-financial-results-on-may-15-2025-302451836.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
When will NRx Pharmaceuticals (NRXP) report Q1 2025 earnings?
How can I access NRXP's Q1 2025 earnings conference call?
Where can I find NRXP's Q1 2025 earnings press release?
What time is NRx Pharmaceuticals' Q1 2025 earnings call?
